<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03066752</url>
  </required_header>
  <id_info>
    <org_study_id>1000054117</org_study_id>
    <nct_id>NCT03066752</nct_id>
  </id_info>
  <brief_title>Cognitive Dysfunction in MS: Using Altered Brain Oscillation to Link Molecular Mechanisms With Clinical Outcomes</brief_title>
  <official_title>Cognitive Dysfunction in MS: Using Altered Brain Oscillation to Link Molecular Mechanisms With Clinical Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to 65% of patients with multiple sclerosis (MS) experience cognitive dysfunction.&#xD;
      Diminution of mental capacity has a pervasive and profound impact on their quality of life.&#xD;
      Subtle changes in white matter predict cognitive changes in these patients but how this&#xD;
      disrupts brain function remains unclear. Development of effective therapeutics to restore&#xD;
      normal cognition hinges on elucidating these functional changes. The investigators seek to&#xD;
      uncover the patho-physiological basis for cognitive decline in MS. The investigators&#xD;
      hypothesize that cognitive decline originates from disrupted gamma oscillations and that&#xD;
      gamma oscillations are disrupted by molecular changes triggered by demyelination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 27, 2017</start_date>
  <completion_date type="Actual">November 24, 2017</completion_date>
  <primary_completion_date type="Actual">November 24, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Neuronal responses during simple and choice reaction time tasks</measure>
    <time_frame>60 minutes</time_frame>
    <description>Video-based eye tracking in the MEG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI scans of the brain, including Diffusion Tensor Imagine (DTI)</measure>
    <time_frame>90 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurocognitive Testing</measure>
    <time_frame>90 minutes</time_frame>
    <description>Penn Computerized Neurocognitive Battery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurological Exam - Standard physical exam performed by the neurologist to determine the Expanded Disability Status Scale (EDSS) score.</measure>
    <time_frame>20 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Interview</measure>
    <time_frame>10 minutes</time_frame>
    <description>Series of questions about the participant's demographic and clinical information including, current and past health, family history, and medications.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Pediatric Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>7 pediatric-onset multiple sclerosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>7 non-patient healthy volunteers</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Seven patients who have pediatric-onset multiple sclerosis and 7 healthy (non-patient)&#xD;
        children are expected to participate in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (*applicable to controls):&#xD;
&#xD;
          1. Must be between 6 and 17 years and 11 months of age*;&#xD;
&#xD;
          2. Have a diagnosis of MS according to the revised McDonald diagnostic criteria and/or&#xD;
             International Pediatric MS Study Group criteria;&#xD;
&#xD;
          3. Has English language knowledge at the level needed to complete clinical questionnaires&#xD;
             (4th grade level).*&#xD;
&#xD;
        Exclusion Criteria (*applicable to controls):&#xD;
&#xD;
          1. Neurological comorbidity.*;&#xD;
&#xD;
          2. Relapses or requires treatment with steroids within 30 days from enrollment;&#xD;
&#xD;
          3. Is pregnant at the time of enrollment.*;&#xD;
&#xD;
          4. Has any metal parts in their body (i.e. Cochlear (ear) implant, metal braces (dental&#xD;
             fillings are o.k.).*;&#xD;
&#xD;
          5. Is younger than 6 years of age.*;&#xD;
&#xD;
          6. Is older than 18 years of age.*;&#xD;
&#xD;
          7. Has prior history of traumatic brain injury, neurological disorder, cerebral palsy,&#xD;
             developmental delay or learning disability.*;&#xD;
&#xD;
          8. Requires sedation for brain scanning.*;&#xD;
&#xD;
          9. Is claustrophobic, as brain scanning requires children to enter a tunnel in the MRI&#xD;
             machine.*&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 3, 2017</study_first_submitted>
  <study_first_submitted_qc>February 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2017</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>E. Ann Yeh</investigator_full_name>
    <investigator_title>Associate Scientist, Research Institute</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

